Work

A Fixed (Weight-independent) Subcutaneous Once-Weekly Dose for Marstacimab, an Anti-TFPI Monoclonal Antibody for the Prophylactic Treatment of Hemophilia Α and B

Year: 2024

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2024-199766

Authors: Satyaprakash Nayak, Akiyuki Suzuki, Patanjali Ravva, Sangeeta V Raje

Institutions: Pfizer (Japan), Pfizer (United States)

Language: English

Topic: Hemophilia Treatment and Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4405041563

Cites:

Cited by: 4

Related to: 10